Pharma, not high-tech, concerns now dominate US patent politics
Shutterstock/f11photo
The first pronouncements from new USPTO Director Kathi Vidal are the latest indication that the centre of gravity in IP debate and policy-making has shifted significantly
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now